Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6][17]. Core Views - The company is experiencing rapid growth in the sugar substitute market, with significant improvements in profitability. Revenue, net profit, and net profit excluding non-recurring items for 2024 are projected to be 1.152 billion, 246 million, and 231 million CNY respectively, representing year-on-year growth of 32.64%, 27.26%, and 31.72% [1]. - The company is benefiting from capacity expansion and strong demand for health-oriented sweeteners, with Q1 revenue from health sweeteners doubling [1][2]. - The overseas market is showing robust demand, with foreign revenue accounting for nearly 70% in Q1 2025, reflecting a year-on-year increase of 11% [2]. Financial Performance Summary - For 2024, the company expects a gross margin of 33.65% and a net profit margin of 21.33%, with improvements in cost management contributing to these figures [3]. - The company’s revenue is projected to grow at a compound annual growth rate (CAGR) of 33% from 2025 to 2027, reaching 1.534 billion, 1.883 billion, and 2.261 billion CNY respectively [4]. - The net profit is expected to grow at a CAGR of 37% from 2025 to 2027, reaching 335 million, 416 million, and 513 million CNY respectively [4]. Market Dynamics - The company is expanding its overseas market presence, with foreign revenue growing significantly due to increasing health trends globally [2]. - The demand for products like allulose is strong, driven by health-conscious consumers [2]. Cost Management - The improvement in gross margin is attributed to reduced operational costs from new production lines and a shift from outsourcing to in-house production of raw materials [3].